Tremelimumab

Posted results on ClinicalTrials.gov for ADRIATIC

• Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (months)
  • Durvalumab vs Placebo: Hazard Ratio (HR) 0.76 (95% CI 0.606 to 0.950), p-value 0.01608, Log Rank, superiority
• Durvalumab Versus Placebo: Overall Survival (OS) (months)
  • Durvalumab vs Placebo: Hazard Ratio (HR) 0.73 (95% CI 0.569 to 0.928), p-value 0.01042, Log Rank, superiority

Serious adverse events (From first dose of study drug(Day 1)upto DCO date 15 January 2024(maximum of approximately 1936 days).Safety population:all participants who received at least 1 dose of study drug.Based on results of secondary objectives at interim analysis(reviewed by unblinded IDMC),data for D+T arm were to remain blinded to Sponsor as pre-specified in study's unblinding plan.Since D+T arm was blinded at time of posting results from this interim analysis,results for that arm will be posted at final analysis.): Durvalumab 78 of 262; Durvalumab Plus Tremelimumab 0 of 0; Placebo 64 of 265

Source: ClinicalTrials.gov results for NCT03703297 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for HIMALAYA

• Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg (months)
  • Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg: Estimate not given, p-value 0.0035, Log Rank, superiority
  • Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg: Hazard Ratio (HR) 0.78 (95% CI 0.66 to 0.92), Regression, Cox, superiority

Serious adverse events (All treatment-emergent adverse events (TEAEs) were collected up to the final analysis DCO (27Aug2021, to a maximum of approximately 46 months).): Durva 1500 mg 115 of 388; Treme 300 mg x1 Dose + Durva 1500 mg 157 of 388; Treme 75 mg x4 Doses + Durva 1500 mg 52 of 152; Sora 400 mg 111 of 374

Source: ClinicalTrials.gov results for NCT03298451 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for STRONG

Serious adverse events (From screening to safety follow up visit (90 days after last dose), maximum up to 4 years.): Durvalumab 254 of 867

Source: ClinicalTrials.gov results for NCT03084471 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for POSEIDON

• Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (months)
  • D + SoC vs SoC Alone: Hazard Ratio (HR) 0.74 (95% CI 0.620 to 0.885), p-value 0.00093, Log Rank, superiority
• Overall Survival (OS); D + SoC Compared With SoC Alone (months)
  • D + SoC vs SoC Alone: Hazard Ratio (HR) 0.86 (95% CI 0.724 to 1.016), p-value 0.07581, Log Rank, superiority

Serious adverse events (Adverse events: from first dose of study treatment until the earlier of 90 days after last dose or the date of first subsequent anticancer therapy. All-cause mortality (death due to any cause): from randomization up to global cohort final analysis DCO (12 March 2021). Maximum timeframe of approximately 45 months.): T + D + SoC 146 of 330; D + SoC 134 of 334; SoC Alone 117 of 333

Source: ClinicalTrials.gov results for NCT03164616 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for CASPIAN

• Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP (months)
  • Global Cohort: D + EP vs Global Cohort: EP: Hazard Ratio (HR) 0.73 (95% CI 0.591 to 0.909), p-value 0.0047, Log Rank, superiority
• OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP (months)
  • Global Cohort: D + EP vs Global Cohort: EP: Hazard Ratio (HR) 0.75 (95% CI 0.625 to 0.910), p-value 0.0032, Log Rank, superiority
  • Global Cohort: D + T + EP vs Global Cohort: EP: Hazard Ratio (HR) 0.82 (95% CI 0.682 to 0.995), p-value 0.0451, Log Rank, superiority
• OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP (months)
  • China Cohort: D + EP vs China Cohort: EP: Hazard Ratio (HR) 0.65 (95% CI 0.414 to 1.029), p-value 0.0664, Log Rank, other

Serious adverse events (All treatment-emergent adverse events (TEAEs) were collected up to the final analysis DCO for each cohort; maximum of approximately 33 months for the Global cohort and maximum of approximately 29 months for the China cohort. Serious AEs and Deaths were collected through LTFU analysis in patients still receiving durvalumab (or within 90 days of discontinuing treatment); up to approximately 4 years.): Global Cohort: D + T + EP 126 of 266; Global Cohort: D + EP 86 of 265; Global Cohort: EP 97 of 266; China Cohort: D + T + EP 31 of 65; China Cohort: D + EP 26 of 61; China Cohort: EP 22 of 62

More posted outcomes or analyses are on the study page. All posted results for NCT03043872

Source: ClinicalTrials.gov results for NCT03043872 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for NEPTUNE

• Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set (months)
  • Global: Durvalumab + Tremelimumab vs Global: SoC Chemotherapy: Hazard Ratio (HR) 0.71 (95% CI 0.485 to 1.045), p-value 0.0808, Log Rank, superiority
• OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set (months)
  • China: Durvalumab + Tremelimumab vs China: SoC Chemotherapy: Hazard Ratio (HR) 0.60 (95% CI 0.322 to 1.109), other

Serious adverse events (Assessed until final analysis DCO for each cohort (24 June 2019 for Global Cohort and 21 September 2020 for China Cohort); maximum timeframe of approximately 44 months for each cohort.): Global: Durvalumab + Tremelimumab 193 of 410; Global: SoC Chemotherapy 112 of 399; China: Durvalumab + Tremelimumab 32 of 77; China: SoC Chemotherapy 22 of 78

Source: ClinicalTrials.gov results for NCT02542293 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for NCT02516241

• To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set (Months)
  • Combination Therapy vs Standard of Care: Hazard Ratio (HR) 0.85 (98.66% CI 0.688 to 1.063), p-value 0.0751, Log Rank, superiority
• To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set (Months)
  • Monotherapy vs Standard of Care: Hazard Ratio (HR) 0.89 (96.99% CI 0.695 to 1.139), p-value 0.3039, Log Rank, superiority

Serious adverse events (From first administration of study treatment up to 90 days after last dose of study medication or date of initiation of the first subsequent therapy, whichever occurs first, approximately 5 years. All-cause mortality, from screening up to data cut-off date (27JAN2020, approximately 5 years).): Combination Therapy 179 of 340; Monotherapy 139 of 345; Standard of Care 125 of 313

Source: ClinicalTrials.gov results for NCT02516241 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for KESTREL

• Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC) (Participants)
  • Durvalumab vs Standard of Care (SOC): Hazard Ratio (HR) 0.96 (95% CI 0.69 to 1.32), p-value 0.787, Log Rank, superiority

Serious adverse events (Adverse events and serious adverse events will be collected from the time of signature of informed consent throughout the treatment period and including the follow-up period (up to 90 days after the last dose of investigational product or until initiation of another therapy) for an average of approximately 4 years.): Durvalumab + Tremelimumab 168 of 408; Durvalumab 78 of 202; Standard of Care (SOC) 94 of 196

Source: ClinicalTrials.gov results for NCT02551159 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for EAGLE

• Overall Survival (OS) (Months)
  • Durvalumab + Tremelimumab vs Standard of Care (SoC): Hazard Ratio (HR) 1.04 (95% CI 0.85 to 1.26), p-value 0.7624, Log Rank, superiority
  • Durvalumab vs Standard of Care (SoC): Hazard Ratio (HR) 0.88 (95% CI 0.72 to 1.08), p-value 0.1993, Log Rank, superiority

Serious adverse events (First dose to last dose + 90 days or data cut off (maximum exposure 32 months)): Durvalumab + Tremelimumab 79 of 246; Durvalumab 69 of 237; Standard of Care (SoC) 61 of 240

Source: ClinicalTrials.gov results for NCT02369874 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for MYSTIC

• Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (months)
  • Durvalumab Monotherapy vs SoC Chemotherapy: Hazard Ratio (HR) 0.76 (97.54% CI 0.564 to 1.019), p-value 0.036, Log Rank, superiority
  • Durvalumab + Tremelimumab vs SoC Chemotherapy: Hazard Ratio (HR) 0.85 (98.77% CI 0.611 to 1.173), p-value 0.202, Log Rank, superiority
• Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy (months)
  • Durvalumab + Tremelimumab vs SoC Chemotherapy: Hazard Ratio (HR) 1.05 (99.5% CI 0.722 to 1.534), p-value 0.705, Log Rank, superiority

Serious adverse events (From first administration of study treatment up to 90 days after last dose of durvalumab and tremelimumab or 30 days after last dose of SoC or date of initiation of the first subsequent therapy, whichever occurs first, approximately 3 years. All-cause mortality, from screening up to data cut-off date (approximately 3 years 1 month).): Durvalumab Monotherapy 131 of 369; Durvalumab + Tremelimumab 178 of 371; SoC Chemotherapy 112 of 352

Source: ClinicalTrials.gov results for NCT02453282 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for ARCTIC

• Overall Survival (OS) (months)
  • Sub-study A: Durvalumab vs Sub-study A: SoC: Hazard Ratio (HR) 0.63 (95% CI 0.42 to 0.93), other
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC: Hazard Ratio (HR) 0.80 (95% CI 0.61 to 1.05), p-value 0.109, Log Rank, superiority
• Progression-Free Survival (PFS) (months)
  • Sub-study A: Durvalumab vs Sub-study A: SoC: Hazard Ratio (HR) 0.71 (95% CI 0.49 to 1.04), other
  • Sub-study B: Durvalumab+Tremelimumab vs Sub-study B: SoC: Hazard Ratio (HR) 0.77 (95% CI 0.59 to 1.01), p-value 0.056, Log Rank, superiority

Serious adverse events (From signature of informed consent up to 90 days after the last dose of durvalumab and/or tremelimumab and 30 days after the last dose of SoC, approximately 15 months.): Sub-study A: Durvalumab 23 of 62; Sub-study A: SoC 16 of 63; Sub-study B: Durvalumab+Tremelimumab 65 of 173; Sub-study B: SoC 28 of 110; Sub-study B: Durvalumab 36 of 117; Sub-study B: Tremelimumab 23 of 60

Source: ClinicalTrials.gov results for NCT02352948 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.